Compare RMBI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | TLSI |
|---|---|---|
| Founded | 1887 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.0M | 270.2M |
| IPO Year | 2019 | 2020 |
| Metric | RMBI | TLSI |
|---|---|---|
| Price | $15.94 | $5.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 40.7K | ★ 165.2K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | N/A | ★ $45,151,000.00 |
| Revenue This Year | N/A | $35.45 |
| Revenue Next Year | N/A | $37.58 |
| P/E Ratio | $31.18 | ★ N/A |
| Revenue Growth | N/A | ★ 53.41 |
| 52 Week Low | $12.77 | $2.20 |
| 52 Week High | $16.59 | $7.95 |
| Indicator | RMBI | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 56.23 |
| Support Level | $15.75 | $4.21 |
| Resistance Level | $16.17 | $5.58 |
| Average True Range (ATR) | 0.25 | 0.27 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 45.69 | 57.47 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.